Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:Q06643 (non-Hodgkin's lymphoma)
 11,307 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This report reviews 85 patients entered into the British National Lymphoma Investigation with localised (clinical Stage 1 and 2) Grade 2 non-Hodgkin's lymphoma, who were treated initially with radiotherapy alone. Almost half of all patients presented with extranodal disease. The duration of follow-up was 20-106 months. There were 33 deaths due to non-Hodgkin's lymphoma. The complete local response rate was dependent on the radiotherapy dose and reached 100% for doses of 4500 cGy or more. Most first failures occurred at a distant nodal site or were due to the development of generalised disease. There was a significant difference in actuarial survival between Stage 1 and Stage 2 patients (P less than 0.005). The 5-year survivals were 78% and 40%, respectively. The site of presenting disease was also important. Stage 1 patients with nodal or ear, nose and throat (ENT) disease had an excellent 5-year survival of 84%, but Stage 2 patients with nodal or ENT disease had a 5-year survival of only 46%. As many of these Stage 2 patients rapidly developed disseminated disease, their survival might have been improved by treatment with chemotherapy before radiotherapy.
 ...
PMID:Localised grade 2 non-Hodgkin's lymphoma: results of treatment with radiotherapy (BNLI Report No. 24). 654 77

Among 169 adult pathologically staged patients with Hodgkin's disease who were treated at the Mayo Clinic between 1974 and 1978, we identified four cases of second malignant lesions that developed. The median duration of follow-up after diagnosis for the entire population was 4.1 years. Of the 169 patients, 73 received irradiation only, 19 received chemotherapy only, and 77 received both chemotherapy and radiation therapy. In all four patients with second malignant lesions, Hodgkin's disease was in apparent remission at the time of diagnosis of the second tumor. These four patients had received either total nodal irradiation or six or more cycles of chemotherapy as initial treatment (and one of them had received both treatment modalities). Thus, intensive therapy might be hypothesized to have played a role in the development of the second malignant tumor. To our knowledge, the development of non-Hodgkin's lymphoma within a previously irradiated field after treatment of Hodgkin's disease with radiation therapy only has not been reported previously. Although further studies with longer follow-up should be conducted, our analysis supports a definite risk for development of a second malignant lesion not only after combined-modality treatment or chemotherapy for Hodgkin's disease but also after irradiation only.
 ...
PMID:Second malignant lesions after therapy for Hodgkin's disease. 658 80

Eight cases of acute nonlymphocytic leukemia and one case of complicating non-Hodgkin's lymphoma were seen over a 15-year period in 408 patients treated for Hodgkin's disease (actuarial risk of acute nonlymphocytic leukemia of 4.9 percent at 12 years). Two cases of leukemia occurred 11 years after diagnosis of Hodgkin's disease. All nine complications were observed in the 220 patients who received MOPP combination therapy (9.1 percent risk of acute nonlymphocytic leukemia at 12 years) either with (n = 8) or without (n = 1) radiation therapy. Patients treated with MOPP with pathologic stage IV disease (37.2 percent risk of acute nonlymphocytic leukemia at 12 years) or over the age of 40 years (33.1 percent risk), and those with failure of MOPP treatment (18.0 percent risk) were in particular jeopardy. If MOPP treatment had been restricted to patients who were under the age of 40 years and with stages I, II, and III disease, it would have been possible to use the drug combination in two thirds of those who had been so treated while eliminating all but one case of leukemia. Furthermore, leukemia was not observed in 78 patients treated with six cycles of MOPP and less than total nodal irradiation. A final decision concerning optimal management of Hodgkin's disease will require definition of the leukemia incidence curve in the second decade after MOPP treatment, and acquisition of additional knowledge of the long-term efficacy and toxicity of alternate treatment regimens.
 ...
PMID:Acute nonlymphocytic leukemia after treatment for Hodgkin's disease. 668 2

The records of 122 patients with non-Hodgkin's lymphoma were reviewed, and the findings of the gallium scan analyzed. The scans of 93 patients were reread without knowledge of the previous readings. Two nuclear medicine physicians agreed with the original readings in 70 per cent of the cases and with each other in 89 per cent of the cases. When the data are analyzed case by case, 52 per cent true positive, 13 per cent false positive and 34 per cent false negative scans were found with only 17 per cent of the scans locating disease not found by routine physical examination and roentgenograms. Looking at individual sites of disease, the gallium scan yields an over-all detection of diseased sites of 18.5 per cent, with 72 per cent of all sites being correctly classified as positive or negative. The diffuse histiocytic, mixed and undifferentiated histologies were detected more accurately than all others, with mediastinal and extranodal sites being identified more frequently than any nodal site. The gallium scan revealed a site of disease which advanced the clinical stage in only one of 122 patients (upstaged). Only one of 122 patients was upstaged as a result of gallium scanning. These data suggest that gallium scanning may not be cost effective in the routine staging of patients with non-Hodgkin's lymphoma.
 ...
PMID:Gallium-67 scanning: limited usefulness in staging patients with non-Hodgkin's lymphoma. 676 31

Data from a study of 342 patients with histologically proven non-Hodgkin's lymphoma treated in Sheffield between 1970-1979 is presented. The Working Formulation for Clinical Usage (National Cancer Institute, 1982) has been applied to histology reviews. The overall 5 year survival was 34.2%. Analysis of data by two factor contingency table analysis of possible prognostic indices showed the favourable effects of low grade histology, localized extranodal staging, asymptomatic (A) status, complete response to initial therapy, high haemoglobin and normal ESR. Unfavourable markers were stage IV disease, histology other than low grade, older age, low haemoglobin and elevated ESR. One hundred and ten cases initially referred to our centre as non-Hodgkin's lymphoma were not histologically acceptable as such, one third of these showed reactive hyperplasia only. A broad spectrum of extra nodal lymphoma was seen in the series (78 patients, 23%); the commonest sites being Waldeyer's ring, gastrointestinal tract, thyroid and skin. Necropsy (50 patients) confirmed that infection, usually bronchopneumonia, in association with persistent lymphoma was the commonest cause of death.
 ...
PMID:Non-Hodgkin's lymphoma in Sheffield 1971-1980. 688 37

The relation between grades of foaminess in lumbar, iliac and inguinal nodes on bipedal lymphograms, and peripheral lymphocyte counts was assessed in patients with untreated non-Hodgkin's lymphoma. The lymphocyte counts were widely distributed in and around the normal range in patients with normal lymphographic findings, but in patients with increased grades of foaminess they were depressed to a marked degree. The decrease in peripheral lymphocyte counts in patients revealing no pathological grades of foaminess may be caused by the occult abdominal non-Hodgkin's lymphoma or may suggest the impending extension of the disease in these nodal chains.
 ...
PMID:Peripheral lymphocyte count in untreated non-Hodgkin's lymphoma patients and their lymphographic findings. 697 Aug 66

As of March 1978, the prognosis was confirmed in 715 non-Hodgkin's lymphoma cases reported during the 12-year period from 1965 through 1976 in the Prefecture of Kagoshima. Included were 222 cases of extranodal lymphoma. Patients with the initial tumor site in the gastrointestinal tract and Waldeyer's ring had a relatively good probability of survival. Among the patients with cutaneous lymphomas, those with the mycosis fungoides type had a poor survival rate. In Kagoshima Prefecture, the survival curve for cases of nodal lymphomas is characteristically much poorer than those reported in the medical literature. Of the nodal lymphomas, the nodular type was found in 128 cases and the five-year survival rate was 15%, while the diffuse type accounted for 365 cases and the five-year survival rate was 8%. The paracortex type, considered to be of T-cell origin, accounted for 55 cases and the five-year survival rate was 0%. These differences were statistically significant. Based on our data, the classification of nodular lymphomas into subtypes according to the degree of nodularity was found to be useful since it was related to clinical stage and survival. Rappaport's cellular classification of diffuse lymphoma is related to prognosis and was found to be useful, but problems still remain in determining T- and B-cell types by means of cellular morphology and thus further study is warranted.
 ...
PMID:Non-Hodgkin's lymphomas in a southern prefecture in Japan: an analysis in 715 cases. 697 Nov 45

Nineteen patients with malignant lymphomas were treated with 52 courses of high dose methotrexate with leucovorin rescue (HDMTX-LCV): 17 non-Hodgkin's lymphoma (11 nodal primary, and 6 Waldeyer's ring), 1 Hodgkin's disease, and 1 Burkitt's lymphoma; 10 No prior chemotherapy, 9 prior chemotherapy; Median age 50 years (18-67); Sex M 13:F 6. MTX was given according to Frei III et al's regimen(1975). In brief, alkalinization of the urine was achieved by administration of NaHCO3 both by oral and by intravenous route. Hydration with at least 3 liters of fluid per day was maintained throughout each course. MTX was administered as a six-hour infusion at an initial dose of 0.5-1.0 g/m2 with gradual escalation to 3-5 g/m2. Thirty minutes before the infusion of MTX, 1.4 mg/m2 of vincristine (VCR) (maximum dose 2 mg) was given intravenously in each course. MTX levels were not monitored. The overall response rate was 63% with 7 partial responses and 5 complete responses. Five of 10 previously untreated patients and 7 of 9 patients with prior chemotherapy achieved an objective response. Our excellent result may be contributed in part by VCR. Although, in general, during this study HDMTX-LCV was well-tolerated, a 67 year-old male had severe and unpredictable toxicity which resulted in shock condition, leukopenia and thrombocytopenia. Accordingly, we feel that HDMTX-LCV is dangerous without monitoring plasma MTX level. In other side effects, peripheral neuropathy and constipation possibly due to VCR occurred especially in elderly patients.
 ...
PMID:[High dose methotrexate with leucovorin rescue in the treatment of malignant lymphoma]. 698 94

The authors reviewed all cases of non-Hodgkin's lymphoma primarily involving the gastrointestinal tract treated at Memorial Hospital during the period from 1949-1978. Complete clinical records were available in 104 cases. Slides of original pathology specimens were available in 81 cases. Tumors were classified by Rappaport, Lukes-Collins and modified Kiel classifications. All patients were staged retrospectively, using modified Ann Arbor staging. The primary tumor was in the stomach in 76 patients, in the small bowel in 15 and in the large bowel in 13. The life-table survival for all patients at five years was 44% and for the 81 Stage I and II patients it was 53%. We found a trend toward improved survival for patients treated in the last decade (P = 0.05). Using Cox regression analysis, survival was found to be correlated with stage (P less than 0.0001) and involvement of adjacent structures (P = 0.007). For Stage I patients, resection and radiation therapy were equally effective alone in controlling local tumor even though factors responsible for the selection of either treatment could not be identified. For Stage II patients, resection combined with radiation therapy controlled local disease better than either treatment alone. For Stage II, patient survival was correlated with the pattern of nodal involvement (P less than 0.0001). Neither the choice of treatment (resection, radiation therapy, or resection with radiation therapy; P = 0.17) nor the involvement of resected margins (P = 0.22) affects survival. Among 81 Stage I and II patients, 68% had recurrences outside the primary field of treatment and 60% outside the abdomen. Systemic multiple modality therapy should be considered for patients at high risk for recurrence.
 ...
PMID:Primary gastrointestinal lymphoma: a 30-year review. 705 47

Forty-eight consecutive previously untreated adults with advanced non-Hodgkin's lymphoma (NHL) of unfavourable histological type were referred to the Department of medical Oncology at St. Bartholomew's Hospital, london, between 1972 and 1977. They received adriamycin, vincristine, prednisolone and L-asparaginase (OPAL) initially, and those in whom complete remission was achieved proceeded to cranial irradiation and intrathecal methotrexate, followed by continuous oral maintenance chemotherapy comprising weekly methotrexate, cyclophosphamide, and daily 6-mercaptopurine for 3 years. Complete remission was achieved in 24 of the 48 (50%). The median duration of remission was 10 months, none patients continuing without relapse for between 3 and 7 years. The median survival was 9 months, 12 patients being alive and disease-free (three in second remission) after between 3 1/2 and 8 1/2 years. The prognosis was significantly better in patients with nodal stages II and III (disease) than in those with stage IV, for both response (P = less than 0.05) and survival (P = 0.002). Patients in whom complete remission was achieved survived significantly longer than those in whom it was not, regardless of stage. These results confirm our preliminary observations with this treatment programme that a proportion of patients with stage II and II unfavourable histology NHL may be curable although the outlook for stage IV remains poor.
 ...
PMID:The treatment of disseminated non-Hodgkin's lymphoma of unfavourable histology. 710 85


<< Previous 1 2 3 4 5 6 7 8 9 10